FDA Approved: TEFLARO — Supplemental Application (Allergan, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for TEFLARO (ceftaroline fosamil) submitted by Allergan, Inc., under NDA 200327.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Community-acquired Bacterial Pneumonia
• Complicated Skin and Skin Structure Infections

Drugs mentioned

• Teflaro (ceftaroline fosamil)

Snippet

SUPPL AP for TEFLARO (CEFTAROLINE FOSAMIL)